Trial Profile
Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications COVID 2019 infections; Pneumonia
- Focus Therapeutic Use
- Acronyms CORIMUNO-19-SARI; CORIMUNO-SARI; SARI-2
- 03 Feb 2022 Results of TOCI-2 trial and SARI-2 study analysis published in the European Respiratory Journal
- 14 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 31 Mar 2020 Planned number of patients changed from 180 to 240.